AR044510A1 - Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina - Google Patents
Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidinaInfo
- Publication number
- AR044510A1 AR044510A1 ARP040101164A ARP040101164A AR044510A1 AR 044510 A1 AR044510 A1 AR 044510A1 AR P040101164 A ARP040101164 A AR P040101164A AR P040101164 A ARP040101164 A AR P040101164A AR 044510 A1 AR044510 A1 AR 044510A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- heteroaryl
- structural formula
- phenyl
- defined above
- Prior art date
Links
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 title abstract 7
- 239000000543 intermediate Substances 0.000 title abstract 3
- 239000002253 acid Substances 0.000 title abstract 2
- 150000007513 acids Chemical class 0.000 title 1
- HZVOZRGWRWCICA-UHFFFAOYSA-N methanediyl Chemical compound [CH2] HZVOZRGWRWCICA-UHFFFAOYSA-N 0.000 abstract 28
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- -1 (1) pyridinyl Chemical group 0.000 abstract 5
- 150000001875 compounds Chemical class 0.000 abstract 5
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 229910052736 halogen Inorganic materials 0.000 abstract 4
- 150000002367 halogens Chemical class 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 abstract 3
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 3
- 125000001624 naphthyl group Chemical group 0.000 abstract 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 abstract 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical group [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 102000001796 Melanocortin 4 receptors Human genes 0.000 abstract 2
- 108010021436 Type 4 Melanocortin Receptor Proteins 0.000 abstract 2
- 150000001414 amino alcohols Chemical class 0.000 abstract 2
- 150000001649 bromium compounds Chemical group 0.000 abstract 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 238000004519 manufacturing process Methods 0.000 abstract 2
- 239000002904 solvent Substances 0.000 abstract 2
- 125000001424 substituent group Chemical group 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000000008 (C1-C10) alkyl group Chemical group 0.000 abstract 1
- 125000004793 2,2,2-trifluoroethoxy group Chemical group FC(CO*)(F)F 0.000 abstract 1
- 125000004206 2,2,2-trifluoroethyl group Chemical group [H]C([H])(*)C(F)(F)F 0.000 abstract 1
- 206010057671 Female sexual dysfunction Diseases 0.000 abstract 1
- 206010057672 Male sexual dysfunction Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 150000001412 amines Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004618 benzofuryl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 abstract 1
- 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 239000003153 chemical reaction reagent Substances 0.000 abstract 1
- 239000003638 chemical reducing agent Substances 0.000 abstract 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 125000002541 furyl group Chemical group 0.000 abstract 1
- 125000005842 heteroatom Chemical group 0.000 abstract 1
- 230000003301 hydrolyzing effect Effects 0.000 abstract 1
- 125000002883 imidazolyl group Chemical group 0.000 abstract 1
- 125000001041 indolyl group Chemical group 0.000 abstract 1
- 125000005956 isoquinolyl group Chemical group 0.000 abstract 1
- 125000001786 isothiazolyl group Chemical group 0.000 abstract 1
- 125000000842 isoxazolyl group Chemical group 0.000 abstract 1
- 150000002576 ketones Chemical class 0.000 abstract 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 abstract 1
- SNVLJLYUUXKWOJ-UHFFFAOYSA-N methylidenecarbene Chemical group C=[C] SNVLJLYUUXKWOJ-UHFFFAOYSA-N 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 125000003373 pyrazinyl group Chemical group 0.000 abstract 1
- 125000003226 pyrazolyl group Chemical group 0.000 abstract 1
- 125000002098 pyridazinyl group Chemical group 0.000 abstract 1
- 125000000714 pyrimidinyl group Chemical group 0.000 abstract 1
- NYCVCXMSZNOGDH-UHFFFAOYSA-N pyrrolidine-1-carboxylic acid Chemical class OC(=O)N1CCCC1 NYCVCXMSZNOGDH-UHFFFAOYSA-N 0.000 abstract 1
- 125000005493 quinolyl group Chemical group 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 125000000335 thiazolyl group Chemical group 0.000 abstract 1
- 125000001544 thienyl group Chemical group 0.000 abstract 1
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Abstract
Se proporciona un procedimiento para preparar ácidos carboxílicos de pirrolidina, y los intermedios útiles obtenidos de los mismos. Estos compuestos son intermedios para la síntesis del receptor de melanocortina-4 (MC-4R), que son útiles para el tratamiento de trastornos tales como obesidad, diabetes, disfunción sexual masculina y disfunción sexual femenina. Reivindicación 1: Un procedimiento para preparar compuestos de fórmula estructural (1) : en la que R1 se selecciona del grupo compuesto por (1) hidrógeno, (2) amidino, (3) alquiliminoilo C1-4, (4) alquilo C1-10, (5) -(CH2)n-cicloalquilo C3-7, (6) -(CH2)n-fenilo, (7) -(CH2)n-naftilo, y (8) -(CH2)n-heteroarilo, en los que el fenilo, naftilo, y heteroarilo están no substituidos o substituidos con uno a tres grupos seleccionados independientemente entre R3; y alquilo, cicloalquilo, y (CH2)n están no substituidos o substituidos con uno a tres grupos seleccionados independientemente entre R3 y oxo; R2 se selecciona del grupo compuesto por (1) alquilo C1-4, (2) -(CH2)n-cicloalquilo, (3) -(CH2)n-heterocicloalquilo, (4) -(CH2)n-fenilo, (5) -(CH2)n-naftilo, y (6) -(CH2)n-heteroarilo en el que heteroarilo se selecciona del grupo compuesto por (1) piridinilo, (2) furilo, (3) tienilo, (4) pirrolilo, (5) oxazolilo, (6) tiazolilo, (7) imidazolilo, (8) pirazolilo, (9) isoxazolilo, (10) isotiazolilo, (11) pirimidinilo, (12) pirazinilo, (13) piridazinilo, (14) quinolilo, (15) isoquinolilo, (16) benzimidazolilo, (17) benzofurilo,(18) benzotienilo, (19) indolilo, (20) benzotiazolilo, y (21) benzoxazolilo; en los que alquilo, fenilo, naftilo, heteroarilo, y (CH2)n están no substituidos o substituidos con uno a tres grupos seleccionados independientemente entre R3; cada R3 se selecciona independientemente del grupo compuesto por (1) alquilo C1-6,(2) -(CH2)n-fenilo, (3) -(CH2)n-naftilo, (4) -(CH2)n-heteroarilo, (5) -(CH2)n-heterocicloalquilo, (6) -(CH2)ncicloalquilo C3-7, (7) halógeno, (8) OR4, (9) -(CH2)nN(R4)2, (10) NO2, (11) -(CH2)nNR4SO2R4, (12) -(CH2)nSO2N(R4)2, (13) -(CH2)nS(O)pR4, (14) CF3, (15) CH2CF3, (16) OCF3, y (17) OCH2CF3; en los que heteroarilo es según se ha definido anteriormente; alquilo, fenilo, naftilo, heteroarilo, cicloalquilo, y heterocicloalquilo están no substituidos o substituidos con uno a tres substituyentes seleccionados independientemente entre halógeno, hidroxi, oxo, alquilo C1-4, trifluorometilo, y alcoxi C1-4; y cualquier átomo de carbono de metileno (CH2) de R3 no está substituido o está substituido con uno a dos grupos seleccionados independientemente entre halógeno, hidroxi, y alquilo C1-4; o dos substituyentes cuando en el mismo grupo metileno (CH2) se toman junto con el átomo de carbono al que están unidos, para formar un grupo ciclopropilo; cada R4 se selecciona independientemente del grupo compuesto por (1) hidrógeno, (2) alquilo C1-6,(3) -(CH2)n-fenilo, (4) -(CH2)n-heteroarilo, (5) -(CH2)n-naftilo, (6) -(CH2)n-heterocicloalquilo, (7) -(CH2)ncicloalquilo C3-7, y (8) -(CH2)nbicicloalquilo C3-7; en los que alquilo, fenilo, heteroarilo, heterocicloalquilo, y cicloalquilo están no substituidos o substituidos con uno a tres grupos seleccionados independientemente entre halógeno, alquilo C1-4, hidroxi, y alcoxi C1-4; o dos grupos R4 junto con el átomo al que están unidos forman un sistema de anillo mono- o bicíclico de 4 a 8 miembros, que contiene opcionalmente, un heteroátomo adicional seleccionado entre O, S, y Nalquilo C1-4; y n es 0, 1, 2, 3 o 4; que comprende las etapas de: (a) preparar un alcohol de fórmula estructural (2) en la que X es bromuro o cloruro, y R2 es según se ha definido anteriormente, tratando una cetona de fórmula estructural (3), en la que X es bromuro o cloruro, y R2 es según se ha definido anteriormente, con un agente reductor, y aislando el producto resultante; (b) formar un amino alcohol de fórmula estructural (4) en la que R1 y R2 son según se han definido anteriormente, tratando el alcohol de fórmula estructural (2) con una amina de fórmula general R1NH2 en la que R1 es según se ha definido anteriormente, y una base en un disolvente, y aislando el producto resultante; (c) formar un compuesto de fórmula estructural (5) en la que Y es -CN o -CO2R5 y R5 es alquilo C1-4, y en la que R1 y R2 son según se han definido anteriormente, tratando el amino alcohol de fórmula estructural (4) con un compuesto de fórmula general (6) en la que Y es -CN o -CO2R5, y R5 es alquilo C1-4, y aislando el producto resultante; (d) formar un compuesto de pirrolidina de fórmula estructural (7) en la que Y, R1 y R2 son según se han definido anteriormente, tratando el compuesto de fórmula estructural (5) con un reactivo activador de alcohol, seguido de una base; (e) formar un ácido de trans-pirrolidina de fórmula estructural (1) en la que R1 y R2 son según se han definido anteriormente, hidrolizando el compuesto de pirrolidina de fórmula estructural (7) con una base acuosa en un disolvente; y (f) aislar el producto resultante.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US46279503P | 2003-04-14 | 2003-04-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR044510A1 true AR044510A1 (es) | 2005-09-14 |
Family
ID=33299992
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040101164A AR044510A1 (es) | 2003-04-14 | 2004-04-06 | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20060199958A1 (es) |
| EP (1) | EP1615882A2 (es) |
| JP (1) | JP2006523700A (es) |
| CN (1) | CN1774419A (es) |
| AR (1) | AR044510A1 (es) |
| CA (1) | CA2521487A1 (es) |
| TW (1) | TW200504011A (es) |
| WO (1) | WO2004092126A2 (es) |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7649002B2 (en) | 2004-02-04 | 2010-01-19 | Pfizer Inc | (3,5-dimethylpiperidin-1yl)(4-phenylpyrrolidin-3-yl)methanone derivatives as MCR4 agonists |
| WO2006123762A1 (ja) * | 2005-05-16 | 2006-11-23 | Sumitomo Chemical Company, Limited | ピロリジン化合物の製造方法 |
| US8013189B2 (en) * | 2007-09-21 | 2011-09-06 | Basf Se | Accelerated amide and ester reductions with amine boranes and additives |
| JPWO2010119848A1 (ja) | 2009-04-14 | 2012-10-22 | アステラス製薬株式会社 | 光学活性ピロリジン化合物の新規製造法 |
| CN104695023B (zh) * | 2015-02-14 | 2017-02-01 | 河北科技大学 | 一水合四氢吡咯‑2‑羧酸单晶及其制备方法 |
| US10550126B2 (en) | 2015-10-16 | 2020-02-04 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| SG10201913997WA (en) | 2015-10-16 | 2020-03-30 | Abbvie Inc | PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF |
| US11773106B2 (en) | 2015-10-16 | 2023-10-03 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11512092B2 (en) | 2015-10-16 | 2022-11-29 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11365198B2 (en) | 2015-10-16 | 2022-06-21 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11524964B2 (en) | 2015-10-16 | 2022-12-13 | Abbvie Inc. | Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof |
| US11034669B2 (en) | 2018-11-30 | 2021-06-15 | Nuvation Bio Inc. | Pyrrole and pyrazole compounds and methods of use thereof |
| BR112021022497A2 (pt) | 2019-11-07 | 2022-05-17 | Lg Chemical Ltd | Composto, composição farmacêutica, uso da composição farmacêutica, e, métodos para prevenir ou tratar obesidade, diabetes, inflamação e disfunção erétil |
| AU2021370072B2 (en) | 2020-10-29 | 2024-02-08 | Lg Chem, Ltd. | Crystalline form iii of melanocortin receptor agonist compound and method for preparing same |
| MX2023004731A (es) | 2020-10-29 | 2023-05-10 | Lg Chemical Ltd | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. |
| AU2021370071B2 (en) | 2020-10-29 | 2024-01-11 | Lg Chem, Ltd. | Amorphous melanocortin-4 receptor agonist |
| CA3195298A1 (en) | 2020-10-29 | 2022-05-05 | Lg Chem, Ltd. | Crystalline form i of melanocortin receptor agonist compound and preparation method therefor |
| AU2021371829B2 (en) | 2020-10-29 | 2024-01-18 | Lg Chem, Ltd. | Crystalline form ii of melanocortin receptor agonist compound and preparation method therefor |
| EP4249483A1 (en) | 2020-12-22 | 2023-09-27 | Lg Chem, Ltd. | Crystalline form i of melanocortin receptor agonist compound and method for preparing same |
| CN116648249A (zh) | 2020-12-22 | 2023-08-25 | 株式会社Lg化学 | 黑皮质素受体激动剂化合物的结晶形式ii及其制备方法 |
| WO2022139446A1 (ko) | 2020-12-22 | 2022-06-30 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅲ 및 이의 제조방법 |
| KR20220090455A (ko) | 2020-12-22 | 2022-06-29 | 주식회사 엘지화학 | 무정형의 멜라노코르틴 수용체 작용제 및 이의 제조방법 |
| TWI826938B (zh) | 2021-02-26 | 2023-12-21 | 南韓商Ｌｇ化學股份有限公司 | 黑皮質素-4受體促效劑 |
| EP4317149A1 (en) | 2021-05-06 | 2024-02-07 | Lg Chem, Ltd. | Crystalline form v of melanocortin receptor agonist compound, and method for preparing same |
| WO2022235105A1 (ko) | 2021-05-06 | 2022-11-10 | 주식회사 엘지화학 | 멜라노코르틴 수용체 작용제 화합물의 결정형 ⅶ 및 이의 제조방법 |
| CA3217468A1 (en) | 2021-05-07 | 2022-11-10 | Lg Chem, Ltd. | Crystal form iv of organic acid salts of melanocortin receptor agonist compound, and preparation method thereof |
| AU2022269992A1 (en) | 2021-05-07 | 2023-11-02 | Lg Chem, Ltd. | Sulfate crystals of melanocortin receptor agonist compound and method of producing same |
| EP4321512A1 (en) | 2021-05-07 | 2024-02-14 | Lg Chem, Ltd. | Co-crystal of melanocortin receptor agonist compound and vanillin and method for preparing same |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU7826398A (en) * | 1997-06-17 | 1999-01-04 | Abbott Laboratories | Pyrrolidine carboxylic acid derivatives as endothelin antagonists |
| EP1383501B1 (en) * | 2001-02-28 | 2007-04-04 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
| US7015235B2 (en) * | 2001-02-28 | 2006-03-21 | Merck & Co., Inc. | Acylated piperidine derivatives as melanocortin-4 receptor agonists |
-
2004
- 2004-04-06 AR ARP040101164A patent/AR044510A1/es unknown
- 2004-04-09 CA CA002521487A patent/CA2521487A1/en not_active Abandoned
- 2004-04-09 EP EP04750027A patent/EP1615882A2/en not_active Withdrawn
- 2004-04-09 WO PCT/US2004/011253 patent/WO2004092126A2/en not_active Application Discontinuation
- 2004-04-09 US US10/550,640 patent/US20060199958A1/en not_active Abandoned
- 2004-04-09 CN CNA2004800098822A patent/CN1774419A/zh active Pending
- 2004-04-09 JP JP2006509940A patent/JP2006523700A/ja not_active Withdrawn
- 2004-04-13 TW TW093110274A patent/TW200504011A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1774419A (zh) | 2006-05-17 |
| CA2521487A1 (en) | 2004-10-28 |
| WO2004092126A3 (en) | 2005-01-20 |
| TW200504011A (en) | 2005-02-01 |
| US20060199958A1 (en) | 2006-09-07 |
| EP1615882A2 (en) | 2006-01-18 |
| WO2004092126B1 (en) | 2005-03-31 |
| WO2004092126A2 (en) | 2004-10-28 |
| JP2006523700A (ja) | 2006-10-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR044510A1 (es) | Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina | |
| ES2594409T3 (es) | Derivados de heteroarilo como moduladores del nAChR á7 | |
| CN104193761B (zh) | 多环化合物及其使用方法 | |
| JP2011126894A5 (es) | ||
| AR096371A1 (es) | 2-fenilimidazo[1,2-a]pirimidinas | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR044036A1 (es) | Compuestos de pirazolopirimidinas y pirazolopiridinas como ligandos de receptor cannabinoide, composiciones farmaceuticas y usos de los mismos | |
| EA200300931A1 (ru) | 5-фенилпиримидины, способ и промежуточные продукты для их получения и их применение для борьбы с фитопатогенными грибами | |
| AR040773A1 (es) | Pirazoles utiles como inhibidores de gsk-3 | |
| RU2018106948A (ru) | Способ получения замещенных производных 3-(2-анилино-1-циклогексил -1н-бензимидазол-5-ил)пропановой кислоты | |
| AR036659A1 (es) | Compuestos derivados de fenil-piperazina, fenil-piperidina y fenil-tetrahidropiridina como inhibidores de la reabsorcion de la serotonina, una composicion farmaceutica y utilizacion de los mismos para la preparacion de medicamentos | |
| GB1378351A (en) | Method for producing functional compounds such as aldehydic acids by treating peroxide derivatives of ozonides of corresponding olefins | |
| CN101677563A (zh) | 5,6-二氢-1h-吡啶-2-酮化合物 | |
| Nayak et al. | Construction of benzo-fused indolizines, pyrrolo [1, 2-a] quinolines via alkyne–carbonyl metathesis | |
| AR051373A1 (es) | Procedimiento para la preparacion de analogos aciclicos de nucleotidos de fosfonatos | |
| AR057525A1 (es) | Compuestos inhibidores selectivos de gsk3 y un proceso para su preparacion | |
| TWI529171B (zh) | １，７－萘啶衍生物 | |
| BRPI1016232A2 (pt) | Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol | |
| HRP20160389T1 (hr) | Derivati orvinola i tevinola korisni u liječenju bolesti ovisnosti o drogama i alkoholu | |
| AR094123A1 (es) | Compuesto triciclicos | |
| Chau et al. | Assembly of a key dienic intermediate for tetrodotoxin via a machetti–desarlo reaction | |
| KR102306860B1 (ko) | 톨-유사 수용체 조정제를 제조하는 방법 | |
| PE20120223A1 (es) | Compuestos heterociclicos como inhibidores del transportador de glicina-1 (glyt-1) | |
| AR092793A1 (es) | Procedimiento para la preparacion de derivados de isoxazolina azetidina quirales como agentes antiparasitarios | |
| AR073842A1 (es) | Derivados del acido 4- dimetilaminobutirico , proceso para su preparacion , composiciones farmacéuticas y uso de los mismos |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |